Image by Vruyr Martirosyan
Publications
arrow&v
  • Management of drug toxicity in M. avium complex pulmonary disease - an expert panel survey.

    2020

    Clin Infect Dis

    van Ingen J, Aliberti S, Andrejak C, et al.

    DIO:

    10.1093/cid/ciaa1361

  • Non-tuberculous mycobacterial lung disease in patients with bronchiectasis: perceived risk, severity and guideline adherence in a European physician survey.

    2020

    BMJ Open Respir Res

    Wagner D, van Ingen J, van der Laan R, et al.

    DIO:

    10.1136/bmjresp-2019-000498

  • COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study.

    2020

    Lancet Child Adolesc Health

    Götzinger F, Santiago-García B, Noguera-Julián A, et al.

    DIO:

    10.1016/S2352-4642(20)30177-2

  • Multidrug-resistant tuberculosis in the Kharkiv Region, Ukraine.

    2020

    Int J Tuberc Lung Dis

    Butov D, Lange C, Heyckendorf J, et al.

    DIO:

    10.5588/ijtld.19.0508

  • Performance of immune-based and microbiological tests in children with tuberculosis meningitis in Europe: a multicentre Paediatric Tuberculosis Network European Trials Group (ptbnet) study.

    2020

    Eur Respir J

    Basu Roy R, Thee S, Blázquez-Gamero D, et al.

    DIO:

    10.1183/13993003.02004-2019

  • The Tuberculosis Network European Trials group (TBnet) ERS Clinical Research Collaboration: addressing drug-resistant tuberculosis through European cooperation.

    2019

    Eur Respir J

    van Leth F, Brinkmann F, Cirillo DM, et al.

    DIO:

    10.1183/13993003.02089-2018

  • Burden and Characteristics of the Comorbidity Tuberculosis-Diabetes in Europe: TBnet Prevalence Survey and Case-Control Study.

    2019

    Open Forum Infect Dis

    Sane Schepisi M, Navarra A, Altet Gomez MN, et al.

    DIO:

    10.1093/ofid/ofy337

  • Tuberculosis disease in children and adolescents on therapy with anti-tumor necrosis factor-alpha agents: a collaborative, multi-centre ptbnet study.

    2019

    Clin Infect Dis

    Noguera-Julian A, Calzada-HernÁndez J, Brinkmann F, et al.

    DIO:

    10.1093/cid/ciz1138

  • Clofazimine does not lead to significant QT interval prolongation: a multicentre study.

    2018

    Eur Respir J

    Zweijpfenning SMH, van Groningen H, van Ingen J, et al.

    DIO:

    10.1183/13993003.01386-2018

  • Use of Xpert MTB/RIF Ultra assays among paediatric tuberculosis experts in Europe.

    2018

    Eur Respir J

    Villanueva P, Neth O, Ritz N, et al.

    DIO:

    10.1183/13993003.00346-2018

  • Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement.

    2018

    Eur Respir J

    van Ingen J, Aksamit T, Andrejak C, et al.

    DIO:

    10.1183/13993003.00170-2018

  • Clinical Management of Multidrug-Resistant Tuberculosis in 16 European Countries.

    2018

    Am J Respir Crit Care Med

    Günther G, van Leth F, Alexandru S, et al.

    DIO:

    10.1164/rccm.201710-2141OC

  • QT prolongation and cardiac toxicity of new tuberculosis drugs in Europe: a Tuberculosis Network European Trialsgroup (TBnet) study.

    2018

    Eur Respir J

    Guglielmetti L, Tiberi S, Burman M, et al.

    DIO:

    10.1183/13993003.00537-2018

  • Tackling the MDR-TB epidemic in Ukraine: every little helps … and much more needed.

    2018

    J Public Health (Oxf)

    Burman M, Nikolayevskyy V, Kontsevaya I, et al.

    DIO:

    10.1093/pubmed/fdx014

  • Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria.

    2017

    Am J Respir Crit Care Med

    van Leth F, Günther G, Hoffmann H, et al.

    DIO:

    10.1164/rccm.201705-0995LE